Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 6976 AL 6990

Melatonin hormone as a therapeutic weapon against neurodegenerative diseases

Asefy Z, Khusro A, Mammadova S, Hoseinnejhad S, Eftekhari A, Alghamdi S, Dablool AS, Almehmadi M, Kazemi E, Sahibzada MUK.

Cell Mol Biol (Noisy-le-grand). 2021 Nov 25;67(3):99-106. doi: 10.14715/cmb/2021.67.3.13.

Recent Advances in the Potential of Cannabinoids for Neuroprotection in Alzheimer's, Parkinson's, and Huntington's Diseases

Pérez-Olives C, Rivas-Santisteban R, Lillo J, Navarro G, Franco R.

Adv Exp Med Biol. 2021;1264:81-92. doi: 10.1007/978-3-030-57369-0_6.

Microglia-derived galectin-3 in neuroinflammation; a bittersweet ligand?

Rahimian R, Béland LC, Sato S, Kriz J.

Med Res Rev. 2021 Jul;41(4):2582-2589. doi: 10.1002/med.21784. Epub 2021 Mar 18.

Pre-Clinical Neuroprotective Evidences and Plausible Mechanisms of Sulforaphane in Alzheimer's Disease

Kim J.

Int J Mol Sci. 2021 Mar 13;22(6):2929. doi: 10.3390/ijms22062929.

When Good Kinases Go Rogue: GSK3, p38 MAPK and CDKs as Therapeutic Targets for Alzheimer's and Huntington's Disease

D'Mello SR.

Int J Mol Sci. 2021 May 31;22(11):5911. doi: 10.3390/ijms22115911.

Emerging hiPSC Models for Drug Discovery in Neurodegenerative Diseases

Trudler D, Ghatak S, Lipton SA.

Int J Mol Sci. 2021 Jul 30;22(15):8196. doi: 10.3390/ijms22158196.

Apoptosis and its therapeutic implications in neurodegenerative diseases

Erekat NS.

Clin Anat. 2022 Jan;35(1):65-78. doi: 10.1002/ca.23792. Epub 2021 Oct 7.

Hypoxia and the Kynurenine Pathway: Implications and Therapeutic Prospects in Alzheimer's Disease

Adeyemi OS, Awakan OJ, Afolabi LB, Rotimi DE, Oluwayemi E, Otuechere CA, Ibraheem O, Elebiyo TC, Alejolowo O, Arowolo AT.

Oxid Med Cell Longev. 2021 Nov 10;2021:5522981. doi: 10.1155/2021/5522981. eCollection 2021.

Insight γ-Secretase: Structure, Function, and Role in Alzheimer's Disease

Mal S, Malik U, Pal D, Mishra A.

Curr Drug Targets. 2021;22(12):1376-1403. doi: 10.2174/1389450121999201230203709.

Cannabinoid receptor 2 selective agonists and Alzheimer's disease: An insight into the therapeutic potentials

Magham SV, Thaggikuppe Krishnamurthy P, Shaji N, Mani L, Balasubramanian S.

J Neurosci Res. 2021 Nov;99(11):2888-2905. doi: 10.1002/jnr.24933. Epub 2021 Sep 6.

Nighttime Agitation and Restless Legs Syndrome in Persons With Alzheimer's Disease: Study Protocol for a Double-Blind, Placebo-Controlled, Randomized Trial (NightRest)

Richards K, Morrison J, Wang YY, Rangel A, Loera A, Hanlon A, Lozano A, Kovach C, Gooneratne N, Fry L, Allen R.

Res Gerontol Nurs. 2020 Nov 1;13(6):280-288. doi: 10.3928/19404921-20200918-01. Epub 2020 Sep 24.

Effects of Myricitrin and Relevant Molecular Mechanisms

Zhang X, Zhang K, Wang Y, Ma R.

Curr Stem Cell Res Ther. 2020;15(1):11-17. doi: 10.2174/1574888X14666181126103338.

Butyrylcholinesterase: A Multifaceted Pharmacological Target and Tool

Ha ZY, Mathew S, Yeong KY.

Curr Protein Pept Sci. 2020;21(1):99-109. doi: 10.2174/1389203720666191107094949.

Novel Therapeutics for the Treatment of Alzheimer's and Parkinson's Disease

Singh K, Yadav D, Chauhan PS, Mishra M, Jin JO.

Curr Pharm Des. 2020;26(7):755-763. doi: 10.2174/1381612826666200107161051.

Alzheimer's Disorder: Epigenetic Connection and Associated Risk Factors

Sharma VK, Mehta V, Singh TG.

Curr Neuropharmacol. 2020;18(8):740-753. doi: 10.2174/1570159X18666200128125641.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias